Has Egils Bogdanovics, MD received payments from drug or device companies?

Yes. Drug and device makers reported $608,240 in general payments to Egils Bogdanovics, MD across 2,168 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Egils Bogdanovics, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Egils Bogdanovics, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Egils Bogdanovics, MD

Endocrinology, Diabetes & Metabolism · Torrington, CTNPI 1619065976

Payments from drug & device makers

$608,240in general payments, 2019–2025

Across 2,168 payments — averaging $280.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novo Nordisk$246K
Dexcom, Inc.$163K
Sanofi-aventis U.S. LLC$40K
Bayer$37K
Johnson & Johnson$27K
Boehringer Ingelheim$23K
plus $73K from 45 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novo Nordisk	499	$245,962
Dexcom, Inc.	242	$163,036
Sanofi-aventis U.S. LLC	118	$39,902
Bayer	129	$36,575
Johnson & Johnson	56	$26,870
Boehringer Ingelheim	116	$22,727
Lilly USA, LLC	198	$22,325
Amgen(2 entities)	143	$15,365
AbbVie	76	$8,591
Mannkind Corporation	53	$7,481
Xeris Pharmaceuticals, Inc.	50	$4,181
Ascensia Diabetes Care US Inc.	19	$3,636
AstraZeneca(2 entities)	129	$2,323
Zealand Pharma US, Inc.	9	$1,727
Corcept Therapeutics	40	$1,096
Abbott	32	$695
IBSA Pharma Inc.	28	$577
Amneal Pharmaceuticals LLC	27	$546
Antares Pharma, Inc.	25	$469
Insulet Corporation	15	$384
Merck	19	$347
Cequr Corporation	4	$326
Medtronic(2 entities)	18	$311
Ascendis Pharma Endocrinology Inc	13	$288
BETA Bionics, Inc.	6	$281
Novartis	14	$280
Tandem Diabetes Care, Inc.	10	$233
Lifescan, Inc.	11	$198
Amryt Pharma Holdings Ltd	6	$150
Embecta Corp.	7	$145
Kyowa Kirin, Inc.	6	$131
Senseonics, Incorporated	1	$130
Halozyme Inc	6	$113
Intra-sana Laboratories	5	$100
BD	5	$91
Ultragenyx Pharmaceutical Inc.	4	$78
Esperion Therapeutics, Inc.	3	$73
Recordati_rare_diseases_inc.	3	$65
Neurocrine Biosciences, Inc.	3	$64
Chiesi USA, Inc.	3	$64
Madrigal Pharmaceuticals	2	$45
Valeritas, Inc.	2	$41
Amarin Pharma, Inc.	3	$40
Shire North American Group Inc	2	$39
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	2	$33
GRT US Holding, Inc.	1	$24
Averitas Pharma Inc.	1	$21
Sequel Med Tech, LLC	1	$16
Companion Medical, Inc.	1	$16
Vistapharm, Inc.	1	$15
Acerus Pharmaceuticals Corporation	1	$14

How this compares

$608,240 in reported general payments places this provider in the 95th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.

See all endocrinology, diabetes & metabolism providers in Connecticut →

Medicare billing

Part B allowed, 2024

$71,125

Medicare patients

391

Services billed

935

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Torrington

Ania JastreboffNew Haven$2.2M
Ilja HulinskyBridgeport$1.6M
Gerald ShulmanNew Haven$1M
Karl InsognaNew Haven$903K
Clemens BergwitzNew Haven$735K
Robert ObersteinHartford$516K
Fadi Al-KhayerStorrs$489K
Silvio InzucchiNew Haven$461K
Francis WilsonNew Haven$415K
Philip GoldbergNew Haven$324K

See the full list for Connecticut →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →